{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:49:09Z","timestamp":1790689749617,"version":"4.1.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,12,28]],"date-time":"2018-12-28T00:00:00Z","timestamp":1545955200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.nmd.2018.12.004","type":"journal-article","created":{"date-parts":[[2018,12,17]],"date-time":"2018-12-17T02:27:59Z","timestamp":1545013679000},"page":"167-186","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":92,"title":["Safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of the novel enzyme replacement therapy avalglucosidase alfa (neoGAA) in treatment-na\u00efve and alglucosidase alfa-treated patients with late-onset Pompe disease: A phase 1, open-label, multicenter, multinational, ascending dose study"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2673-7145","authenticated-orcid":false,"given":"Loren D.M.","family":"Pena","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Barohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry J.","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1847-5381","authenticated-orcid":false,"given":"Claude","family":"Desnuelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozlem","family":"Goker-Alpan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shafeeq","family":"Ladha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Lafor\u00eat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl Eugen","family":"Mengel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Pestronk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Pouget","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt","family":"Schoser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9046-3540","authenticated-orcid":false,"given":"Volker","family":"Straub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaya","family":"Trivedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4010-2357","authenticated-orcid":false,"given":"Philip","family":"Van Damme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Vissing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Kacena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raheel","family":"Shafi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth L.","family":"Thurberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry","family":"Culm-Merdek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ans T.","family":"van der Ploeg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nmd.2018.12.004_bib0001","series-title":"The metabolic and molecular bases of inherited disease","first-page":"3389","article-title":"Glycogen storage disease type II: acid alpha-glucosidase (acid maltase) deficiency","author":"Hirschhorn","year":"2001"},{"key":"10.1016\/j.nmd.2018.12.004_bib0002","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/S0140-6736(08)61555-X","article-title":"Pompe's disease","volume":"372","author":"van der Ploeg","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.nmd.2018.12.004_bib0003","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s11910-011-0236-5","article-title":"Enzyme replacement therapy for Pompe disease","volume":"12","author":"Angelini","year":"2012","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1016\/j.nmd.2018.12.004_bib0004","first-page":"123","article-title":"Pathology of skeletal muscle cells in adult-onset glycogenosis type II (Pompe disease): ultrastructural study","volume":"46","author":"Lewandowska","year":"2008","journal-title":"Folia Neuropathol"},{"key":"10.1016\/j.nmd.2018.12.004_bib0005","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1002\/ajmg.a.36110","article-title":"Timing of diagnosis of patients with Pompe disease: data from the Pompe registry","volume":"161A","author":"Kishnani","year":"2013","journal-title":"Am J Med Genet A"},{"key":"10.1016\/j.nmd.2018.12.004_bib0006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ymgme.2011.02.004","article-title":"Pompe disease: design, methodology, and early findings from the Pompe Registry","volume":"103","author":"Byrne","year":"2011","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.nmd.2018.12.004_bib0007","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00415-005-0922-9","article-title":"The natural course of non-classic Pompe's disease; a review of 225 published cases","volume":"252","author":"Winkel","year":"2005","journal-title":"J Neurol"},{"key":"10.1016\/j.nmd.2018.12.004_bib0008","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/2051-5960-2-2","article-title":"The value of muscle biopsies in Pompe disease: identifying lipofuscin inclusions in juvenile- and adult-onset patients","volume":"2","author":"Feeney","year":"2014","journal-title":"Acta Neuropathol Commun"},{"key":"10.1016\/j.nmd.2018.12.004_bib0009","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ymgme.2010.08.001","article-title":"Differences in the predominance of lysosomal and autophagic pathologies between infants and adults with Pompe disease: implications for therapy","volume":"101","author":"Raben","year":"2010","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.nmd.2018.12.004_bib0010","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.jsb.2008.03.010","article-title":"Detection and imaging of non-contractile inclusions and sarcomeric anomalies in skeletal muscle by second harmonic generation combined with two-photon excited fluorescence","volume":"162","author":"Ralston","year":"2008","journal-title":"J Struct Biol"},{"key":"10.1016\/j.nmd.2018.12.004_bib0011","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s10545-015-9825-9","article-title":"Skeletal muscle quantitative nuclear magnetic resonance imaging follow-up of adult Pompe patients","volume":"38","author":"Carlier","year":"2015","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.nmd.2018.12.004_bib0012","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s10545-010-9204-5","article-title":"Changes in skeletal muscle qualities during enzyme replacement therapy in late-onset type II glycogenosis: temporal and spatial pattern of mass vs. strength response","volume":"33","author":"Ravaglia","year":"2010","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.nmd.2018.12.004_bib0013","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1007\/s00256-009-0797-4","article-title":"Adult onset glycogen storage disease type II (adult onset Pompe disease): report and magnetic resonance images of two cases","volume":"38","author":"Del Gaizo","year":"2009","journal-title":"Skeletal Radiol"},{"key":"10.1016\/j.nmd.2018.12.004_bib0014","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1750-1172-7-88","article-title":"Clinical features and predictors for disease natural progression in adults with Pompe disease: a nationwide prospective observational study","volume":"7","author":"van der Beek","year":"2012","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.nmd.2018.12.004_bib0015","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.pediatrneurol.2011.12.010","article-title":"Early pathologic changes and responses to treatment in patients with later-onset Pompe disease","volume":"46","author":"Chien","year":"2012","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.nmd.2018.12.004_bib0016","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.ymgme.2012.09.017","article-title":"Severely impaired health status at diagnosis of Pompe disease: a cross-sectional analysis to explore the potential utility of neonatal screening","volume":"107","author":"Rigter","year":"2012","journal-title":"Mol Genet Metab"},{"issue":"Suppl 2","key":"10.1016\/j.nmd.2018.12.004_bib0017","doi-asserted-by":"crossref","first-page":"S148","DOI":"10.1016\/j.nmd.2012.05.011","article-title":"Trunk muscle involvement in late-onset Pompe disease: study of thirty patients","volume":"22","author":"Alejaldre","year":"2012","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2018.12.004_bib0018","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1212\/01.WNL.0000165979.46537.56","article-title":"Disease severity in children and adults with Pompe disease related to age and disease duration","volume":"64","author":"Hagemans","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2018.12.004_bib0019","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1750-1172-6-34","article-title":"Survival and associated factors in 268 adults with Pompe disease prior to treatment with enzyme replacement therapy","volume":"6","author":"G\u00fcng\u00f6r","year":"2011","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.nmd.2018.12.004_bib0020","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1038\/labinvest.3700484","article-title":"Characterization of pre- and post-treatment pathology after enzyme replacement therapy for Pompe disease","volume":"86","author":"Thurberg","year":"2006","journal-title":"Lab Invest"},{"key":"10.1016\/j.nmd.2018.12.004_bib0021","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ymgme.2016.05.013","article-title":"Prospective exploratory muscle biopsy, imaging, and functional assessment in patients with late-onset Pompe disease treated with alglucosidase alfa: The EMBASSY Study","volume":"119","author":"van der Ploeg","year":"2016","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.nmd.2018.12.004_bib0022","doi-asserted-by":"crossref","first-page":"50336","DOI":"10.1074\/jbc.M409676200","article-title":"Conjugation of mannose 6-phosphate-containing oligosaccharides to acid \u03b1-glucosidase improves the clearance of glycogen in Pompe mice","volume":"279","author":"Zhu","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.nmd.2018.12.004_bib0023","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/mt.2009.37","article-title":"Glycoengineered acid \u03b1-glucosidase with improved efficacy at correcting the metabolic aberrations and motor function deficits in a mouse model of Pompe disease","volume":"17","author":"Zhu","year":"2009","journal-title":"Mol Ther"},{"key":"10.1016\/j.nmd.2018.12.004_bib0024","unstructured":"Genzyme Corporation. MYOZYME\u00ae (alglucosidase alfa) Prescribing information. https:\/\/www.myozyme.com\/\u223c\/media\/MyozymeUS\/Files\/Documents\/mz_pi.pdf; May 2014 [accessed 2 November, 2017]."},{"key":"10.1016\/j.nmd.2018.12.004_bib0025","unstructured":"Genzyme Corporation. LUMIZYME\u00ae (alglucosidase alfa) Prescribing information. https:\/\/www.lumizyme.com\/\u223c\/media\/LumizymeUS\/Files\/lumizyme_prescribing_information.pdf; August 2014 [accessed 2 November, 2017]."},{"key":"10.1016\/j.nmd.2018.12.004_bib0026","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/GIM.0b013e31819d0996","article-title":"Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease","volume":"11","author":"Nicolino","year":"2009","journal-title":"Genet Med"},{"key":"10.1016\/j.nmd.2018.12.004_bib0027","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1212\/01.wnl.0000251268.41188.04","article-title":"Recombinant human acid \u03b1-glucosidase: major clinical benefits in infantile-onset Pompe disease","volume":"68","author":"Kishnani","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2018.12.004_bib0028","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa0909859","article-title":"A randomized study of alglucosidase alfa in late-onset Pompe's disease","volume":"362","author":"van der Ploeg","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmd.2018.12.004_bib0029","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ymgme.2012.09.015","article-title":"Open-label extension study following the Late-Onset Treatment Study (LOTS) of alglucosidase alfa","volume":"107","author":"van der Ploeg","year":"2012","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.nmd.2018.12.004_bib0030","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/1750-1172-7-73","article-title":"Effect of enzyme therapy and prognostic factors in 69 adults with Pompe disease: an open-label single-center study","volume":"7","author":"de Vries","year":"2012","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.nmd.2018.12.004_bib0031","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.nurt.2008.08.009","article-title":"Therapeutic approaches in glycogen storage disease type II\/Pompe Disease","volume":"5","author":"Schoser","year":"2008","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.nmd.2018.12.004_bib0032","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ymgme.2003.08.022","article-title":"Enzyme replacement therapy in the mouse model of Pompe disease","volume":"80","author":"Raben","year":"2003","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.nmd.2018.12.004_bib0033","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ymgme.2011.02.006","article-title":"Enhanced efficacy of enzyme replacement therapy in Pompe disease through mannose-6-phosphate receptor expression in skeletal muscle","volume":"103","author":"Koeberl","year":"2011","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.nmd.2018.12.004_bib0034","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.ymgme.2008.04.009","article-title":"Biochemical and pharmacological characterization of different recombinant acid alpha-glucosidase preparations evaluated for the treatment of Pompe disease","volume":"94","author":"McVie-Wylie","year":"2008","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.nmd.2018.12.004_bib0035","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1021\/bc1005416","article-title":"Strategies for neoglycan conjugation to human acid alpha-glucosidase","volume":"22","author":"Zhou","year":"2011","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.nmd.2018.12.004_bib0036","year":"2002"},{"key":"10.1016\/j.nmd.2018.12.004_bib0037","unstructured":"European Medicines Agency. International conference on harmonization topic M3 (R2) non-clinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals, https:\/\/www.ema.europa.eu\/en\/ich-m3-r2-non-clinical-safety-studies-conduct-human-clinical-trials-pharmaceuticals. 2013 [accessed 20 December, 2018]."},{"key":"10.1016\/j.nmd.2018.12.004_bib0038","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1164\/ajrccm.159.1.9712108","article-title":"Spirometric reference values from a sample of the general U.S. population","volume":"159","author":"Hankinson","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.nmd.2018.12.004_bib0039","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1177\/002215540505300108","article-title":"High-resolution light microscopy (HRLM) and digital analysis of Pompe disease pathology","volume":"53","author":"Lynch","year":"2005","journal-title":"J Histochem Cytochem"},{"key":"10.1016\/j.nmd.2018.12.004_bib0040","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1164\/rccm.166.4.518","article-title":"ATS\/ERS Statement on respiratory muscle testing","volume":"166","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.nmd.2018.12.004_bib0041","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.4187\/respcare.09541348","article-title":"The assessment of maximal respiratory mouth pressures in adults","volume":"54","author":"Evans","year":"2009","journal-title":"Respir Care"},{"key":"10.1016\/j.nmd.2018.12.004_bib0042","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1164\/ajrccm.166.1.at1102","article-title":"ATS statement: guidelines for the six-minute walk test","volume":"166","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.nmd.2018.12.004_bib0043","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1164\/ajrccm.158.5.9710086","article-title":"Reference equations for the six-minute walk in healthy adults","volume":"158","author":"Enright","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.nmd.2018.12.004_bib0044","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1177\/1756285609103324","article-title":"Progress in enzyme replacement therapy in glycogen storage disease type II","volume":"2","author":"Angelini","year":"2009","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.nmd.2018.12.004_bib0045","series-title":"Gross motor function measure (GMFM-66 & GMFM-88) user's manual","author":"Russell","year":"2002"},{"key":"10.1016\/j.nmd.2018.12.004_bib0046","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s10545-011-9388-3","article-title":"The quick motor function test: a new tool to rate clinical severity and motor function in Pompe patients","volume":"35","author":"van Capelle","year":"2012","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.nmd.2018.12.004_bib0047","doi-asserted-by":"crossref","unstructured":"Varni J.W. Pediatric Quality of Life Inventory Scoring Manual; 1998.","DOI":"10.1037\/t65932-000"},{"key":"10.1016\/j.nmd.2018.12.004_bib0048","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/gim.2016.70","article-title":"Pompe disease in adulthood: effects of antibody formation on enzyme replacement therapy","volume":"19","author":"de Vries","year":"2017","journal-title":"Genet Med"},{"key":"10.1016\/j.nmd.2018.12.004_bib0049","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ymgme.2012.04.027","article-title":"The impact of antibodies in late-onset Pompe disease: a case series and literature review","volume":"106","author":"Patel","year":"2012","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.nmd.2018.12.004_bib0050","article-title":"Effects of short-to-long term enzyme replacement therapy (ERT) on skeletal muscle tissue in late onset Pompe disease (LOPD)","author":"Ripolone","year":"2017","journal-title":"Neuropathol Appl Neurobiol"},{"key":"10.1016\/j.nmd.2018.12.004_bib0051","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.ymgme.2005.03.010","article-title":"Glucose tetrasaccharide as a biomarker for monitoring the therapeutic response to enzyme replacement therapy for Pompe disease","volume":"85","author":"An","year":"2005","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.nmd.2018.12.004_bib0052","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/ajmg.c.31320","article-title":"Assessing disease severity in Pompe disease: the roles of a urinary glucose tetrasaccharide biomarker and imaging techniques","volume":"160C","author":"Young","year":"2012","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"10.1016\/j.nmd.2018.12.004_bib0053","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s00415-016-8219-8","article-title":"Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis","volume":"264","author":"Schoser","year":"2017","journal-title":"J Neurol"},{"key":"10.1016\/j.nmd.2018.12.004_bib0054","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/1750-1172-8-160","article-title":"The clinical relevance of outcomes used in late-onset Pompe disease: can we do better?","volume":"8","author":"Lachmann","year":"2013","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.nmd.2018.12.004_bib0055","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.ymgme.2013.06.023","article-title":"Late-onset Pompe disease (LOPD): correlations between respiratory muscles CT and MRI features and pulmonary function","volume":"110","author":"Gaeta","year":"2013","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.nmd.2018.12.004_bib0056","first-page":"255","article-title":"Effects of respiratory muscle training (RMT) in children with infantile-onset Pompe disease and respiratory muscle weakness","volume":"7","author":"Jones","year":"2014","journal-title":"J Pediatr Rehabil Med"},{"key":"10.1016\/j.nmd.2018.12.004_bib0057","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ymgme.2015.09.003","article-title":"Respiratory muscle training (RMT) in late-onset Pompe disease (LOPD): Effects of training and detraining","volume":"117","author":"Jones","year":"2016","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.nmd.2018.12.004_bib0058","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ymgme.2011.06.012","article-title":"Rate of progression and predictive factors for pulmonary outcome in children and adults with Pompe disease","volume":"104","author":"van der Beek","year":"2011","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.nmd.2018.12.004_bib0059","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s10545-014-9751-2","article-title":"Ten years of the international Pompe survey: patient reported outcomes as a reliable tool for studying treated and untreated children and adults with non-classic Pompe disease","volume":"38","author":"van der Meijden","year":"2015","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.nmd.2018.12.004_bib0060","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ymgme.2013.03.016","article-title":"Enzyme replacement therapy and fatigue in adults with Pompe disease","volume":"109","author":"G\u00fcng\u00f6r","year":"2013","journal-title":"Mol Genet Metab"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896617314633?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896617314633?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T14:44:15Z","timestamp":1775313855000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896617314633"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":60,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S0960896617314633"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2018.12.004","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of the novel enzyme replacement therapy avalglucosidase alfa (neoGAA) in treatment-na\u00efve and alglucosidase alfa-treated patients with late-onset Pompe disease: A phase 1, open-label, multicenter, multinational, ascending dose study","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2018.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}